CLAIM #33812 · Johnson & Johnson (JNJ) · 2023Q4 earnings call · Jan 23, 2024 · due Dec 31, 2024
“We have filed all the three indications, and we expect approval of that in 2024.”
Joaquin Duato · CEO
CANNOT_DETERMINE
versus commitment · official band 5 percent
Committed
We have filed all the three indications, and we expect approval of that in 2024.
Reported
we received FDA approval for RYBREVANT in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR Exon 20 Insertion Mutations
Verify independently
SEC filings for JNJ ↗ · Claim quote is verbatim from the 2023Q4 earnings call.